Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac ®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents.

MLA

Fadlyana, Eddy, et al. “Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac ®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents.” Vaccines, vol. 12, no. 8, Aug. 2024, p. 938. EBSCOhost, https://doi.org/10.3390/vaccines12080938.

APA

Fadlyana, E., Rusmil, K., Dwi Putra, M. G., Fulendry, F. P., Somantri, N. K., Putri, A. D., Sari, R. M., Puspita, M., & Dewi, G. P. (2024). Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac ®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents. Vaccines, 12(8), 938. https://doi.org/10.3390/vaccines12080938

Chicago

Fadlyana, Eddy, Kusnandi Rusmil, Muhammad Gilang Dwi Putra, Frizka Primadewi Fulendry, Nitta Kurniati Somantri, Alvira Dwilestarie Putri, Rini Mulia Sari, Mita Puspita, and Gianita Puspita Dewi. 2024. “Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac ®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents.” Vaccines 12 (8): 938. doi:10.3390/vaccines12080938.